source
- GSK's mRNA flu vaccine shows stronger immune response than standard shots in phase 2, prompting phase 3 launchGSK reported that its experimental mRNA seasonal influenza vaccine generated higher immune responses than both standard and high-dose flu shots in a phase-2 study involving nearly 1,000 adults. Th…
- Novartis reports positive multiple sclerosis results with its BTK inhibitorNovartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area. The result highlights the…